Speaker Details

Brian Kirby

Brian Kirby

SESSIONS

S050 Late-Breaking Research: Session 2
Mar 10, 2024 • 1:00 PM - 4:00 PM • Room 20B

DISCLOSURES

AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Almirall – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Honoraria); Celgene – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Eli Lilly – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Advisory Board(Honoraria); MC2 Therapeutics – Consultant (1099 relationship)(Honoraria); Merck & Co., Inc – Consultant (1099 relationship)(Grants/Research Funding), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Honoraria); Novartis – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Honoraria); UCB – Advisory Board(Honoraria), Investigator(Grants/Research Funding);